Development of a ‘Cerium-DTPA’ complex, a new drug candidate for the treatment of sepsis

A metal product produced in vitro demonstrates clinical potential as a treatment for sepsis

[메디컬투데이=이재혁 기자] A domestic research team has developed a metal substance treatment candidate that is produced outside the body while reducing systemic inflammation and organ damage caused by sepsis.

Through joint research, a joint research team led by Professor Kim Chi-kyung from the Department of Neurology at Korea University Guro Hospital designed a cerium-based material in the form of a prodrug that does not accumulate in the body, which removed toxicity, and apply it. he went to sepsis, a systemic inflammatory disease, to develop metal-based nanomaterials.

Sepsis is a dangerous disease that causes excessive inflammatory reactions in the body and can cause multiple organ damage and shock throughout the body.

Current sepsis treatment has limitations in controlling the inflammatory response, and in particular, it is difficult to effectively control oxidative stress caused by reactive oxygen species (ROS), making it an area that requires ongoing research.

To solve this problem, inorganic nanoparticles with stronger antioxidant and anti-inflammatory properties than existing drugs have been considered as treatment candidates, but their clinical use has been limited due to concerns about long-term toxicity. time due to metal accumulation in the body.

To overcome these limitations, Professor Kim’s research team developed a cerium-DTPA complex, a new therapeutic candidate that can be produced in vitro and reduces excessive inflammatory responses.

The complex developed by the research team prevents the burning of cerium ions by creating nanoparticles that can be removed from the body through the intestines with to use iron-DTPA together, the antioxidant and anti-inflammatory effects are increased and it is confirmed that it does not accumulate, thus preventing drug toxicity Concerns were rejected.

Subsequently, the researchers confirmed the effectiveness of the metal production system in treating sepsis in animal experiments. The researchers injected a metal prodrug treatment into the blood vessels of experimental mice that had induced sepsis As a result, the expression of cytokine storm was reduced, organ damage in the liver, spleen, and reduce the kidneys, and the survival rate was about 5 times more than the untreated group An increase was confirmed.

Professor Kim Chi-kyung said, “Sepsis is a systemic inflammatory response, and there is still no single treatment drug. He said, “Through this study, there is a need for continued research on application materials.” “We will strive to accelerate research and develop a single treatment for sepsis in the future.”

CTO Somin said, “It will be a very important turning point for the commercialization of nanomedicines. clinical trials.” “He explained the meaning of this achievement.

Medical Today Reporter Jaehyuk Lee ([email protected])

[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]